Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maraviroc + zidovudine + lamivudine
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Maraviroc + zidovudine + lamivudine is a combination antiretroviral therapy used in the treatment of HIV infection. Maraviroc is a small molecule CCR5 co-receptor antagonist that blocks the entry of CCR5-tropic HIV-1 into human cells by allosterically modifying the CCR5 receptor, thereby preventing viral fusion and entry[4][8]. Zidovudine and lamivudine are both nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase by incorporating into viral DNA and causing chain termination, thus blocking viral replication[2][6]. This combination targets different stages of the HIV life cycle to reduce viral load and slow disease progression. The regimen is indicated for use in adults with confirmed CCR5-tropic HIV infection as part of a complete antiretroviral regimen[4].
- Brand names
- Combivir
- Other names
- CCR5 antagonist + AZT + 3TC
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseCCR5 (C-C chemokine receptor type 5)
Beyond the preview
Go deeper on maraviroc + zidovudine + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maraviroc + zidovudine + lamivudine.